Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
HCWB | US
-0.03
-8.23%
Healthcare
Biotechnology
30/06/2024
24/04/2026
0.38
0.38
0.39
0.36
HCW Biologics Inc. a clinical-stage biopharmaceutical company focuses on discovering and developing novel immunotherapies for chronic low-grade inflammation and age-related diseases. The company's lead products include HCW9218 which is an injectable immunotherapeutic for patients with pancreatic ovarian breast prostate and colorectal cancers as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases such as alopecia areata and metabolic diseases. It also develops HCW9201 a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar Florida.
View LessLow Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
121.5%1 month
143.4%3 months
215.8%6 months
174.3%-
-
2.80
-1.59
0.37
-3.63
7.66
-
-36.58M
16.39M
16.39M
-
-2.24K
-
-0.60
-344.32
0.87
0.14
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.14
Range1M
0.20
Range3M
1.21
Rel. volume
0.87
Price X volume
168.27K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 2.91 | 17.74M | 0.00% | n/a | 0.00% |
| ICU | ICU | Biotechnology | 4.13 | 17.31M | -2.59% | n/a | -45.50% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 5.47 | 16.65M | -2.67% | n/a | 10.72% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.5939 | 16.07M | 4.19% | n/a | 1.90% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.52 | 15.50M | 0.00% | n/a | 54.59% |
| iBio Inc | IBIO | Biotechnology | 1.68 | 15.35M | -7.18% | n/a | 20.92% |
| Lexaria Bioscience Corp | LEXX | Biotechnology | 0.9438 | 14.92M | 0.10% | n/a | 1.41% |
| NeuroSense Therapeutics Ltd. Ordinary Shares | NRSN | Biotechnology | 0.7501 | 14.86M | 4.92% | n/a | -2.11% |
| Cocrystal Pharma Inc | COCP | Biotechnology | 1.43 | 14.55M | 1.42% | n/a | 10.24% |
| Longeveron Inc. Class A Common Stock | LGVN | Biotechnology | 0.94 | 13.50M | -3.73% | n/a | 11.72% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.63 | 0.53 | Cheaper |
| Ent. to Revenue | 7.66 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.80 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 215.83 | 72.80 | Riskier |
| Debt to Equity | -1.59 | -1.23 | Cheaper |
| Debt to Assets | 0.37 | 0.25 | Expensive |
| Market Cap | 16.39M | 3.66B | Emerging |